These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7000851)

  • 1. Future prospects for use of fibrinolysis inhibitors.
    Verstraete M
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():77-80. PubMed ID: 7000851
    [No Abstract]   [Full Text] [Related]  

  • 2. [Protease inhibitors and antifibrinolytic therapy].
    Manrique R
    Arq Bras Cardiol; 1984 Nov; 43(5):355-60. PubMed ID: 6242229
    [No Abstract]   [Full Text] [Related]  

  • 3. Protease inhibitors in the treatment of hereditary angioedema.
    Ritchie BC
    Transfus Apher Sci; 2003 Dec; 29(3):259-67. PubMed ID: 14572819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Principles and limitations in the use of protease inhibitors as antifibrinolytic agents].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1967; 88(2):109-22. PubMed ID: 4174648
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preliminary report on the local treatment of joints with the protease-inhibitor Contrykal].
    Engler J
    Dtsch Gesundheitsw; 1969 Nov; 24(46):2195-6. PubMed ID: 5385553
    [No Abstract]   [Full Text] [Related]  

  • 6. [Creation of synthetic serine proteinase inhibitors, an important pharmacological problem].
    Markwardt F
    Farmakol Toksikol; 1978; 41(5):530-3. PubMed ID: 359347
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
    Zahedi R; Wisnieski J; Davis AE
    J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of an enzyme inhibitor in cicatrization. (Animal experimentation; application to hand surgery)].
    Comtet JJ; Migne J; Fischer L
    Ann Chir Plast; 1972; 17(2):145-9. PubMed ID: 5043659
    [No Abstract]   [Full Text] [Related]  

  • 9. The past, present and future of plasmin inhibitor.
    Aoki N
    Thromb Res; 2005; 116(6):455-64. PubMed ID: 16181980
    [No Abstract]   [Full Text] [Related]  

  • 10. Current and future therapy for hereditary angioedema.
    Zuraw BL
    Clin Immunol; 2005 Jan; 114(1):10-6. PubMed ID: 15596404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CU-2010--a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties.
    Dietrich W; Nicklisch S; Koster A; Spannagl M; Giersiefen H; van de Locht A
    Anesthesiology; 2009 Jan; 110(1):123-30. PubMed ID: 19104179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological therapies of systemic lupus erythematosus].
    Olesińska M; Chwalińska-Sadowska H; Mielnik P; Wiesik-Szewczyk E
    Pol Merkur Lekarski; 2006 Mar; 20(117):371-3. PubMed ID: 16780279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of trasylol as an inhibitor of proteases of the fibrinolysis system during extracorporeal circulation].
    Masiak M; Bross W
    Folia Med Cracov; 1980; 22(3-4):455-61. PubMed ID: 6169610
    [No Abstract]   [Full Text] [Related]  

  • 14. Acquired C1-inhibitor deficiency in a patient with systemic lupus erythematosus: a case report and review of the literature.
    Nettis E; Colanardi MC; Loria MP; Vacca A
    Eur J Clin Invest; 2005 Dec; 35(12):781-4. PubMed ID: 16313255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contraception by inhibitors of acrosomal proteinase].
    Zhou YC
    Sheng Li Ke Xue Jin Zhan; 1986 Jul; 17(3):221-4. PubMed ID: 3541179
    [No Abstract]   [Full Text] [Related]  

  • 16. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema.
    Khan S; Tarzi MD; Doré PC; Sewell WA; Longhurst HJ
    Clin Immunol; 2007 Apr; 123(1):14-7. PubMed ID: 17098477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of antifibrinolytic agents used in hemostatic fibrin sealants.
    Busuttil RW
    J Am Coll Surg; 2003 Dec; 197(6):1021-8. PubMed ID: 14644291
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antifibrinolytic therapy].
    Levi M; ten Cate JW
    Ned Tijdschr Geneeskd; 1995 Mar; 139(12):613-7. PubMed ID: 7700404
    [No Abstract]   [Full Text] [Related]  

  • 19. [Heparin and fibrinolysis inhibitors].
    Villaverde CA; Badimón L; Vidal M; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1981 Apr; 7(1):97-100. PubMed ID: 7325724
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiproteolytic activity in foetal organs with low fibrinolytic potential.
    Fornasari PM; Gratton L; Gamba G; Pandolfi M
    Boll Soc Ital Biol Sper; 1976 Jun; 52(11):767-9. PubMed ID: 1016626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.